Bispecific Antibodies
Bispecific Antibodies in Oncology and Beyond: Clinical Advances, Market Growth, and China’s Emergence
Bispecific antibodies are reshaping oncology and beyond. By 2025, 20 products are approved, with 2024 sales topping $126.5B led by Hemlibra and Vabysmo. China leads the pipeline with 35+ trials, two domestic approvals, and global partnerships.